Furthermore, after 52 weeks of treatment, the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) improved significantly among participants in the tirzepatide arm compared with those in the placebo arm (between-group difference = 6.9 [95% CI 3.310.6]
The real question is what it means for Indian healthcare, pharmaceutical innovation, and how we approach preventive medicine going forward
Gut microbiota-derived short-chain fatty acids, T cells, and inflammation
Sometimes the "cheaper" option ends up costing more when you factor in months of use without results, hidden subscription fees, and the eventual pivot to something that actually works
If you want the broader context, start with the BPC-157 hub page, then use the deep dives for mechanism, evidence, safety and status, and quality and COA